Symbols

QTRX

Quanterix·NASDAQ

--(--)

QTRX fundamentals

QTRX Q4 2025 Earnings

Quanterix (QTRX) released its earnings on Mar 2, 2026: revenue was 43.85M (YoY +24.72%), beat estimates; EPS was -0.49 (YoY -63.33%), missed estimates.

Revenue / YoY

43.85M

+24.72%

EPS / YoY

-0.49

-63.33%

Report date

Mar 2, 2026

QTRX Earnings Call Summary for Q4,2025

Revenue Growth: Q4 2025 revenue of $43.9M (+25% YoY), driven by Simoa and Spatial platforms
Diagnostics Breakthrough: CMS approves $897 reimbursement rate for LucentAD complete; FDA 510(k) submission filed
Cost Efficiency: $74M of $85M cost synergies achieved, targeting H2 2026 cash flow breakeven
Innovation Pipeline: 13 new assays launched in 2025, Simoa ONE platform in early access testing
Strategic Expansion: 25+ diagnostics partnerships generating $9.6M in 2025, oncology pipeline expansion
Financial Health: $122M cash on hand, no debt, targeting $100M by year-end

Earnings

EPS

Revenue

Revenue & Expenses

QTRX has released its 2025 Q4 earnings report, with revenue of 43.85M, reflecting a YoY change of 24.73%, and net profit of -23.12M, showing a YoY change of -98.80%. The Sankey diagram below clearly presents QTRX's revenue sources and cost distribution.

Key Indicators

Quanterix (QTRX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Quanterix (QTRX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Quanterix (QTRX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Quanterix (QTRX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown